Pharmigene, Inc. (7595) Stock Statistics & Valuation Metrics
Total Valuation
Pharmigene, Inc. has a market cap or net worth of TWD 408.77M. The enterprise value is ―.
- Market Cap
- TWD 408.77M
- Enterprise Value
- ―
Share Statistics
Pharmigene, Inc. has 50,465,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 50,465,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Pharmigene, Inc.’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -5.88%.
- Return on Equity (ROE)
- -0.26
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -5.88%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 4.08M
- Profits Per Employee
- -1.49M
- Employee Count
- 49
- Asset Turnover
- 0.20
- Inventory Turnover
- 3.64
Valuation Ratios
The current PE Ratio of Pharmigene, Inc. is -7.72. Pharmigene, Inc.’s PEG ratio is -0.24.
- PE Ratio
- -7.72
- PS Ratio
- 2.16
- PB Ratio
- 1.55
- Price to FCF
- -54.45
- Price to Operating Cash Flow
- -97.34
- PEG Ratio
- -0.24
Income Statement
In the last 12 months, Pharmigene, Inc. had revenue of 199.89M and earned -73.00M in profits. Earnings per share was -1.45.
- Revenue
- 199.89M
- Gross Profit
- 38.91M
- Operating Income
- -54.96M
- Pretax Income
- -72.97M
- Net Income
- -73.00M
- EBITDA
- -29.26M
- Earnings Per Share (EPS)
- -1.45
Cash Flow
In the last 12 months, operating cash flow was -4.14M and capital expenditures -3.30M, giving a free cash flow of -7.44M billion.
- Operating Cash Flow
- -4.14M
- Free Cash Flow
- -7.44M
- Free Cash Flow per Share
- -0.15
Dividends & Yields
Pharmigene, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.89%
- Earnings Yield
- -13.34%
Stock Price Statistics
- Beta
- -0.28
- 52-Week Price Change
- -25.69%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 62.40
- Average Volume (3m)
- 33.37K
Financial Position
Pharmigene, Inc. as a current ratio of 1.58, with Debt / Equity ratio of 235.26%
- Current Ratio
- 1.58
- Quick Ratio
- 1.26
- Debt to Market Cap
- 1.31
- Net Debt to EBITDA
- -20.46
- Interest Coverage Ratio
- -3.80
Taxes
In the past 12 months, Pharmigene, Inc. has paid 25.00K in taxes.
- Income Tax
- 25.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Pharmigene, Inc. EV to EBITDA ratio is -42.17, with an EV/FCF ratio of -126.64.
- EV to Sales
- 5.02
- EV to EBITDA
- -42.17
- EV to Free Cash Flow
- -126.64
- EV to Operating Cash Flow
- -227.38
Balance Sheet
Pharmigene, Inc. has TWD 92.58M in cash and marketable securities with TWD 636.45M in debt, giving a net cash position of -TWD 543.86M billion.
- Cash & Marketable Securities
- TWD 92.58M
- Total Debt
- TWD 636.45M
- Net Cash
- -TWD 543.86M
- Net Cash Per Share
- -TWD 10.78
- Tangible Book Value Per Share
- TWD 4.98
Margins
Gross margin is 28.01%, with operating margin of -23.86%, and net profit margin of -27.82%.
- Gross Margin
- 28.01%
- Operating Margin
- -23.86%
- Pretax Margin
- -27.82%
- Net Profit Margin
- -27.82%
- EBITDA Margin
- -11.89%
- EBIT Margin
- -23.86%
Analyst Forecast
The average price target for Pharmigene, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 25.80%
- EPS Growth Forecast
- 30.78%
